# Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

> **NCT05983237** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jun Guo** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Fluzoparib Camrelizumab Temozolomide

## Key facts

- **NCT ID:** NCT05983237
- **Lead sponsor:** Jun Guo
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983237, "Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05983237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*